The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-advisors-split-regimens-breast-prostate-cancers-2026a1000f3j?src=rss
Author :
Publish date : 2026-05-11 13:14:00
Copyright for syndicated content belongs to the linked Source.
